Both studies describe outcomes before and after anti-VEGF therapies were introduced in the local clinical practice, and both reported a nearly 50% drop in the incidence rate of legal blindness by AMD since anti-VEGF was introduced [12, 22]. The gene discussed is VEGFA; the disease is age-related macular degeneration.